Annals of Oncology 7:129-133, 1996
© 1996 European Society for Medical Oncology
other |
Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer
1Department of Haematology/Oncology, Georg-August-University Góttingen, Germany
2Department of Pathology II, Georg-August-University Góttingen, Germany
3Department of Clinical Chemistry, Georg-August-University, Góttingen, Germany
Dr. Claudia Binder Dept of Haematology/Oncology Georg-August-University Robert-Koch-Str. 40 D-37075 Göttingen Germany
Background: It has been suggested that modification of the physiological susceptibility to induction of programmed cell death in transformed cells contributes to the pathogenesis of cancer. One of the major regulators of cell death is the bcl-2 family. In breast cancer, altered expression of Bcl-2 has been described. Distribution of its counterpart Bax and the differential expression pattern have still to be evaluated.
Patients and methods: Bax expression was investigated by immunohistochemistry in 122 primary breast cancers. Results were correlated with expression of Bcl-2 and other variables of predictive value.
Results: There was a positive association between Bax expression and histological grading, (over)expression of c-erbB-1 and -2 and proliferative activity. The correlation was most significant in cases where no concomitant Bcl-2 expression could be detected. In the same subgroup an inverse correlation with positivity for estrogen (and progesterone) receptors was observed. The presence of Bax was not significantly associated with either tumor type and size, nodal status or expression of c-erbB-3.
Conclusion: Expression of Bax was coupled with negative histopathological features, especially when expression of Bcl-2 was downregulated concomitantly. It may appear that alterations of the differential Bax/Bcl-2 expression pattern take part in deregulation of proliferation and loss of differentiation, thus playing an important role in malignant progression.
Bax, Bcl-2, breast cancer, prognostic factors
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Tangkeangsirisin, J. Hayashi, and G. Serrero PC Cell-Derived Growth Factor Mediates Tamoxifen Resistance and Promotes Tumor Growth of Human Breast Cancer Cells Cancer Res., March 1, 2004; 64(5): 1737 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Tong, M. H. Papayoti, G. Netto, D. T. Armstrong, G. Ordonez, J. M. Lawson, and M. J. Stone Growth-inhibitory Effects of CD40 Ligand (CD154) and Its Endogenous Expression in Human Breast Cancer Clin. Cancer Res., March 1, 2001; 7(3): 691 - 703. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Shilkaitis, J. Graves, R. R. Mehta, L. Hu, M. You, R. Lubet, V. Steele, G. Kelloff, and K. Christov Bcl-2 and Bax Are Differentially Expressed in Hyperplastic, Premalignant, and Malignant Lesions of Mammary Carcinogenesis Cell Growth Differ., August 1, 2000; 11(8): 437 - 445. [Abstract] [Full Text]
|
|
|
|
|
|
S. Renner, J. Weisz, S. Krajewski, M. Krajewska, J. C. Reed, and A. Lichtenstein Expression of BAX in Plasma Cell Dyscrasias Clin. Cancer Res., June 1, 2000; 6(6): 2371 - 2380. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. A. Hogarth and A. G. Hall Increased BAX Expression Is Associated With an Increased Risk of Relapse in Childhood Acute Lymphocytic Leukemia Blood, April 15, 1999; 93(8): 2671 - 2678. [Abstract] [Full Text] [PDF]
|
|